DYN

ANALYST NOTE: DYNE THERAPEUTICS, INC. (DYN) DATE: 2026-06-13

(1) Structural Readiness As of the close on 2026-06-13, DYN presents a confirmed coil setup, indicating a breakout has fired. The conservative entry level for this structure is $25.63. The current price is $25.90, representing an extension of +1.1% above the conservative entry. The setup exhibits high structural quality, evidenced by an ATR at breakout of 5.5% and a current ATR of 5.3%, both falling within the high volatility sweet spot (4–6%) historically associated with robust trend continuations. The presence of a confirmed coil suggests the market has absorbed supply and is currently in an actionable phase of the setup.

(2) The Thesis Layer DYN is a direct beneficiary of the Biotech & GLP-1 → Rare & Orphan secular theme. The company operates as a clinical-stage biopharmaceutical company focused on genetically driven neuromuscular diseases, specifically targeting Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy Type 1 (DM1), and Facioscapulohumeral Dystrophy (FSHD). The conviction in this thesis is high due to the company's proprietary FORCE platform and the specific alignment of its lead asset, z-rostudirsen, with the urgent unmet medical needs of the DMD patient population. The company is positioned to capture value in the "Rare & Orphan" segment where regulatory pathways (such as Accelerated Approval) and pricing power are structurally distinct from mass-market therapeutics.

(3) The Business Dyne Therapeutics, Inc. is a clinical-stage company developing a portfolio of product candidates for rare neuromuscular diseases. As of the date of this analysis, the company's primary business driver is the development of z-rostudirsen (DYNE-251) for DMD patients amenable to exon 51 skipping.

• Regulatory Milestones: Management has stated that following a positive pre-BLA meeting with the FDA, they plan to submit a Biologics License Application (BLA) for U.S. Accelerated Approval in the second quarter of 2026. The submission is based on dystrophin as a surrogate endpoint. Management expects a potential U.S. launch of z-rostudirsen in the first quarter of 2027, assuming FDA grants priority review and approval is received on the anticipated timeline.
• Pipeline Expansion: The company is assembling a broad portfolio. Management plans to initiate a global confirmatory Phase 3 clinical trial of z-rostudirsen in the second quarter of 2026, having aligned with the FDA on the trial design. Additionally, they plan to submit a BLA for z-basivarsen (for DM1) in the third quarter of 2027, with a potential launch in Q1 2028.
• Capitalization: In a filing dated 2026-05-11, management stated that cash, cash equivalents, and marketable securities are sufficient to fund operating expenses, debt service, and capital expenditure requirements for at least 12 months from the issuance of the financial statements.
• Recent Capital Activity: As of late July 2026 (post-event date context for the filing, but relevant to the capital structure leading into June), the company announced the pricing and closing of an upsized $375 million public offering of common stock, indicating strong institutional demand and liquidity to support the Phase 3 initiation and BLA submission.

(4) The Archetype and Conviction DYN fits the Growth Leader archetype. The company is transitioning from a pure clinical-stage entity to a near-commercial biotech with a defined regulatory path (BLA submission) and a clear launch timeline (Q1 2027).

• Conviction Drivers:
• Thesis Strength: High confidence in the Rare & Orphan theme; DMD is a high-prevalence orphan disease with a clear market need.
• Evidence Quality: Strong alignment with the FDA on Phase 3 design and BLA submission strategy. The "positive pre-BLA meeting" is a critical validation of the surrogate endpoint strategy.
• Structural Quality: The ATR metrics (5.5% at breakout, 5.3% current) indicate healthy volatility and institutional participation without the extreme risk of >8% ATR.
• Rerating Potential: The market is currently pricing in the successful BLA submission and the subsequent Priority Review. The confirmation of the $375M offering suggests the market is willing to fund the next leg of growth.

(5) Invalidation, Strengthening, and Gaps

• Strengthening Factors: Successful FDA acceptance of the BLA (which was announced in news dated 2026-07-30, but the *expectation* of acceptance was the thesis driver in June), the initiation of the Phase 3 trial as planned in Q2 2026, and the continued alignment with the FDA on the confirmatory trial design.
• Invalidation Factors: A delay in the BLA submission beyond Q2 2026, a negative response from the FDA regarding the surrogate endpoint (dystrophin), or a failure to secure the necessary capital to fund the 12-month runway.
• Gaps in Evidence: While the BLA submission is planned, the actual FDA decision (PDUFA date) is not yet known as of 2026-06-13. The clinical data from the confirmatory Phase 3 trial is also not yet available, as the trial is set to *initiate* in Q2 2026. The long-term commercial uptake and pricing dynamics for z-rostudirsen remain unproven.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key evidence: Confirmed coil breakout with high ATR structural quality; FDA alignment on Phase 3 design and BLA submission strategy for z-rostudirsen; Sufficient cash runway to fund operations for 12 months. Key risks: FDA rejection of the surrogate endpoint (dystrophin) or delay in BLA acceptance; execution risk in initiating the global Phase 3 trial; dilution from recent capital raises impacting per-share value. Rating boundary: This is rated Buy rather than Strong Buy because the BLA has not yet been formally accepted and the PDUFA date is not set; the "Strong Buy" notch would require confirmed FDA acceptance of the BLA and a clear PDUFA date. It is not rated lower because the structural setup is confirmed and the regulatory path is explicitly defined by management. Sizing hint: Position size should reflect the high volatility (ATR ~5.3%) and the binary nature of the upcoming regulatory events, utilizing the confirmed breakout level for risk management. Expected path: Management expects to submit the BLA in Q2 2026, followed by a Priority Review and a potential launch in Q1 2027. The stock should trade on the probability of these milestones being met. Expected horizon: 12 to 18 months, covering the BLA submission, FDA review, and the initiation of the confirmatory Phase 3 trial. Failure mode to watch: A formal communication from the FDA indicating that the dystrophin surrogate endpoint is insufficient for Accelerated Approval, which would force a restart of the development program.